Biotech Spotlight


  • Caroline Loew, chief executive officer of Mural Oncology
    Image attribution tooltip
    Permission granted by Mural Oncology
    Image attribution tooltip
    Q&A

    Why a former BMS exec calls her new CEO role ‘unfinished business’ in cancer care

    With a focus on her “three pillars” of being a CEO, Caroline Loew explains how she’s building a new company culture at an Alkermes spinoff — and a pipeline that offers a next-gen approach to oncology.  

    By Alexandra Pecci • Feb. 6, 2024
  • 4D Molecular Therapeutics CEO David Kirn
    Image attribution tooltip
    Permission granted by 4DMT
    Image attribution tooltip
    Q&A // Biotech Spotlight

    One biotech’s 3 gene therapy hurdles: delivery, delivery and delivery

    4DMT’s David Kirn is looking to the future of gene therapy with delivery methods that change the paradigm.

    By Jan. 10, 2024
  • Gene editing
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    This biotech aims to expand the CRISPR toolkit for more disease targets in the liver and brain

    Arbor Biotechnologies is looking past CRISPR’s recent regulatory wins and into the next stage of gene editing.

    By Dec. 19, 2023
  • Lindsay Pino, co-founder, chief technology officer, Talus Bio
    Image attribution tooltip
    Permission granted by Talus Bio
    Image attribution tooltip
    Biotech Spotlight

    A biotech tackles drug discovery with transcription factor know-how

    Talus Bio, which developed a platform to map transcription factors, has a lead cancer candidate in the works and consults with other industry players in the complicated biology.

    By Nov. 15, 2023
  • Sarah Boyce, CEO and president, Avidity Biosciences
    Image attribution tooltip
    Permission granted by Avidity
    Image attribution tooltip
    Biotech Spotlight

    A new delivery method muscling its way into the RNA space

    With an AOC platform targeting muscle diseases, Avidity Biosciences hopes to break open the possibilities of RNA.

    By Kelly Bilodeau • Nov. 8, 2023
  • vaccine ampoules on red
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    Cidara’s J&J-partnered immunotherapy could target flu and cancer

    On a roll with promising data, the commercial-stage biotech is leveraging drug-Fc conjugates to aim a new weapon at viral targets.

    By Alexandra Pecci • Oct. 26, 2023
  • Antibodies autoimmune disease
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    An ‘inverse vaccine’ takes aim at autoimmune diseases

    Backed by Pfizer, Anokion’s innovative approach to treating celiac, MS and more is showing early promise where others failed.

    By Kelly Bilodeau • Oct. 23, 2023
  • pediatric cancer concept
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    To close the pediatric innovation gap, this biotech has to think differently

    Day One Biopharmaceuticals is bucking the cancer drug development trend by working with children and adults simultaneously.

    By Alexandra Pecci • Oct. 11, 2023
  • dna tube
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    A biotech ‘tuning’ the genome for a potentially safer gene therapy

    Tune Therapeutics is hoping to overcome the pitfalls of CRISPR-style treatments with epigenetic editing.

    By Kelly Bilodeau • Oct. 9, 2023
  • highway
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    Immuneering takes aim at cancer’s ‘superhighway’

    After dropping its neuroscience program earlier this year, the clinical-stage oncology company is doubling down on a candidate targeting the MAPK pathway.

    By Kelly Bilodeau • Sept. 11, 2023
  • Test tube blood
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    ‘We need to do better:’ A biotech CEO on standing apart from the crowd

    The CEO of Cullinan Oncology is taking a small biotech to the next step and believes the temporary financial barriers are smaller than scientific progress.

    By Aug. 29, 2023
  • Brain scans are seen in a stock image
    Image attribution tooltip
    sudok1 via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    Brii Biosciences aims to come up big where Sage and Biogen fell short

    The depression space recently got a stinging FDA rebuke — but Brii thinks it can break through with improved formulations.

    By Kelly Bilodeau • Aug. 21, 2023
  • Michael Severino, CEO, Tessera Therapeutics
    Image attribution tooltip
    Permission granted by Tessera
    Image attribution tooltip
    Q&A // Biotech Spotlight

    Why AbbVie’s former president has high hopes for this Flagship-backed biotech

    The CEO of Tessera Therapeutics believes the company’s gene writing technology could eventually cure nearly any genetic disease across patient populations.

    By Karissa Waddick • Aug. 7, 2023
  • Liver model
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    How CymaBay overcame a NASH failure for another shot at liver disease success

    The biotech’s 2019 trial halt was a major disappointment in NASH, but a turnaround has shown late-stage potential in another liver disease with unmet needs.

    By Aug. 2, 2023
  • Aerial view of Shanghai at night
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    Zai Lab looks to expand beyond China and make a global impact in oncology

    Focused on making a “transformational” impact, the company is developing targeted treatments driven by specific cancer mutations.

    By Kelly Bilodeau • June 12, 2023
  • Bahija Jallal Immunocore 2
    Image attribution tooltip
    Permission granted by Bahija Jallal
    Image attribution tooltip
    Q&A // Biotech Spotlight

    How Immunocore’s Bahija Jallal embraced the ‘a-ha’ moment of promising science

    The biotech CEO is bullish on the company’s pioneering T cell receptor platform and innovating new immunology-based treatments.

    By May 5, 2023
  • Pills of varying colors lay on top a map of the human brain
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    Emalex aims at a first-in-class breakthrough for Tourette syndrome

    With its phase 3 candidate, the biotech believes it can move the field beyond antipsychotics to a more effective approach.

    By Kelly Bilodeau • May 1, 2023
  • DNA sequencing gel
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    This biotech’s ‘Microsoft’ approach could change how we see gene therapy

    The company’s using a unique component-based platform to develop functional cures for diseases, including HIV.

    By Karissa Waddick • March 20, 2023
  • Babson Diagnostics
    Image attribution tooltip
    Permission granted by Babson Diagnostics
    Image attribution tooltip
    Q&A

    Babson aims to shed Theranos curse with new blood testing tech

    Babson Diagnostics is trying to create a less invasive blood testing technology — can it gain trust in the post-Theranos era?

    By Kelly Bilodeau • March 13, 2023
  • Cooked vegetables in black plastic containers
    Image attribution tooltip
    Permission granted by Faeth
    Image attribution tooltip
    Q&A // Biotech Spotlight

    While many leverage precision medicine, Faeth is banking on precision nutrition to tackle cancer

    The San Francisco-based biotech is pairing metabolically-engineered diets with existing therapies to starve and kill tumors.

    By Karissa Waddick • March 9, 2023
  • A  3D illustration of ribonucleic acid, or RNA, strands
    Image attribution tooltip
    Christoph Burgstedt via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    Launched with a ‘pioneer’ in RNA, aTyr Pharma is charting a new course in immunology

    With a focus on rare and hard-to-treat diseases, aTyr is banking on its head start in tRNA and vast IP portfolio to build a billion-dollar company.

    By March 2, 2023
  • Faby Malik Cytokinetics
    Image attribution tooltip
    Permission granted by Dr. Faby Malik, Cytokinetics
    Image attribution tooltip
    Q&A // Biotech Spotlight

    Cytokinetics looks to muscle into the cardiovascular market

    With a scientific platform based on muscle biology, the late-stage biotech is addressing cardiovascular and neuromuscular diseases.

    By Feb. 24, 2023
  • vaccine vial
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A // First 90 Days

    Pheast’s new CEO on how its ‘don’t eat me’ platform could deliver next-gen precision immunotherapies

    Jacopo Leonardi’s latest venture is in the burgeoning field of macrophage inhibitors that could target a wide range of cancers.

    By Feb. 17, 2023
  • Cancer antibodies
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    Nectin’s Keytruda combo could fill gaps in immuno-oncology’s treatment paradigm

    The Israeli biotech just entered into a collaboration with Merck to develop its own checkpoint inhibitor alongside the bestselling cancer treatment.

    By Feb. 16, 2023
  • Jill Milne Astria Therapeutics
    Image attribution tooltip
    Permission granted by Jill Milne, Astria Therapeutics
    Image attribution tooltip
    Q&A // Biotech Spotlight

    Astria Therapeutics’ edge in an ultra-rare disease

    With positive early phase data, CEO Jill Milne is aiming to bring an improved preventative option to patients with hereditary angioedema.

    By Feb. 1, 2023